Clinical trials: Diabetes Mellitus Type 2 With Proteinuria
Type 2 Diabetes, Proteinuria
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include: 1.
- Conditions
- Type 2 Diabetes, Proteinuria, Stress, Nephropathy
- Trial name
- iCARE (NCT02818192)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University of Manitoba
Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
The goal of this clinical trial is to determine the feasibility of remote clinical trial conduct in patients with type 2 diabetes and elevated albuminuria.
- Conditions
- Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes
- Trial name
- Optimize@Home (NCT06094920)
- Testing
- Empagliflozin 10 MG, Finerenone, Withings BPM Connect
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Type 2 Diabetes Mellitus
Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors
Given the inadequacies of existing pharmacological interventions for diabetic nephropathy, this study is predicated on the hypothesis that silymarin, having shown promise in mitigating hyperglycemia in diabetic patients without…
- Trial name
- NCT06425705
- Testing
- Silymarin
- Where
- Pakistan
- Volunteers
- 70 people
- Sponsor
- Lahore General Hospital
Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
Randomized placebo-controlled double-blind cross-over N=1 trial in adult male and female patients with UACR >20 mg/g (2.26 mg/mmol) with type 2 diabetes treated in primary or secondary healthcare.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Diabetes
- Trial name
- @HOME (NCT06374043)
- Testing
- Dapagliflozin 10mg Tab, Withings BPM Connect, Withings Body+
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Type 2 Diabetes, Chronic Kidney Disease
Kidney Biopsy Indications in Type 2 Diabetes Patients
The WHO (World Health Organisation) estimated the prevalence of diabetes to be 422 million people in 2014, compared to 108 million in 1980.
- Trial name
- RIB-R2D2 (NCT04006028)
- Where
- 4 sites in France
- Volunteers
- 500 people
- Sponsor
- Rennes University Hospital
Diabetes Mellitus, Diabetic Nephropathy
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme…
- Trial name
- NCT00754143
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kyntra Bio
Type 2 Diabetes Mellitus, Proteinuria
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas
Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03983551
- Testing
- Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
- Volunteers
- 101 people
- Sponsor
- Changhua Christian Hospital
Proteinuria, Hypertension
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.
- Conditions
- Proteinuria, Hypertension, Type II Diabetes
- Trial name
- NCT01804777
- Testing
- Amiloride, HCTZ
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of New Mexico
Type 2 Diabetes
Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients
This multi-center, randomized controlled study aims to evaluate the effects of pentoxifylline on proteinuria in Korean type 2 diabetic patients.
- Trial name
- NCT01382303
- Testing
- Pentoxifylline
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Ajou University School of Medicine
Type 2 Diabetes
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
Proteinuria is an independent risk factor for cardiovascular morbidity and mortality and for renal disease progression. More proteinuria is associated with faster progression, whereas treatments that reduce proteinuria are…
- Trial name
- PROCEED (NCT01393808)
- Testing
- Paricalcitol
- Where
- 6 sites in Italy
- Volunteers
- 112 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Type 2 Diabetes Mellitus, Nephropathy
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy.
- Trial name
- NCT00655330
- Testing
- Valsartan, Probucol
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Guangdong Provincial People's Hospital
Diabetic Nephropathy, Persistent Proteinuria With Type II Diabetes
Renal Denervation in Diabetic Nephropathy
The DERENEDIAB study is a proof-of-concept, multi-center, prospective, open, randomized, controlled study of the effectiveness of renal denervation in addition to standardized medical treatment compared to medical treatment alone…
- Trial name
- DERENEDIAB (NCT01588795)
- Testing
- Percutaneous renal denervation and TMNS, Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Preeclampsia, Type 1 Diabetes
Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus
A tonic active epithelial Na+ channel (ENaC) in pre-eclampsia (PE) escaped normal hormonal control may offer an attractive explanatory model for the pathophysiology of established PE. The channel is activated by plasmin.
- Trial name
- NCT01821053
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Odense University Hospital
Type 2 Diabetes, Diabetic Nephropathy
Pioglitazone and Losartan Provides Additional Renoprotection
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II…
- Trial name
- NCT00364988
- Testing
- pioglitazone+losartan, losartan
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
- Trial name
- NCT01464320
- Testing
- ABT-614
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abbott
PROTEINURIA, Hypertension
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
- Conditions
- PROTEINURIA, Hypertension, Type 2 Diabetes
- Trial name
- NCT00241085
- Testing
- valsartan
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Novartis
Type 2 Diabetes, Overt Diabetic Nephropathy
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
- Trial name
- NCT00324675
- Testing
- Rosiglitazone
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Technische Universität Dresden
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Type 2
How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?
Pioglitazone is an insulin sensitising drug used in the treatment of patients with type 2 diabetes. In addition to its blood sugar lowering effect, pioglitazone also has a number of other beneficial effects, one of which is to…
- Trial name
- NCT00749047
- Testing
- Pioglitazone
- Where
- New Zealand
- Volunteers
- 12 people
- Sponsor
- Christchurch Hospital